Transplantation of engineered vascularized lymphatic tissue using LEC and in vivo AV loop model to enhance lymphangiogenesis and restore lymphatic drainage in a lymphadenectomy rat model.
Mackert GA., Hsiao HY., Chang YC., Wu RT., Dang RR., Tee R.
Animal Study, published in J Tissue Eng (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Tissue Eng (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40792201
- PMCID
- PMC12336406
- DOI
- 10.1177/20417314251360755
Abstract (original English)
Lymphedema has emerged as a significant health issue among cancer survivors. The primary goal of treatment is to restore lymphatic drainage function. Engineering vascularized lymphatic tissue offers a promising alternative to achieve this goal. Currently, lymphatic tissue engineering with the use of cell-seeded scaffolds incubated in high hemodynamic flow environments, such as AV loop chambers, has shown promising results for lymphatic vessel regeneration. In this study, lymphatic endothelial cells (LECs) and adipose-derived stem cells (ASCs) were incorporated into an AV loop chamber and cultured in the groin region of a rat model. Surprisingly, the level of lymphangiogenesis, indicated by increased expression of the lymphatic marker LYVE-1, was significantly higher in the group with LECs alone than in the group with both LECs and ASCs. The engineered lymphatic tissue was subsequently orthotopically transplanted into the area of lymph node dissection. This procedure restored lymphatic drainage and reduced local inflammation, with decreased levels of CD3, CD4, and CD8 expression. These findings provide the potential for creating a functional, organized lymphatic system through the engineering of vascularized lymphatic tissue via AV loop cultivation, offering an applicable treatment option for lymphatic defects.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.